Discovery of OSI-906: A Selective and Orally Efficacious Dual Inhibitor of the IGF-1 Receptor and Insulin Receptor
Future Medicinal Chemistry2009Vol. 1(6), pp. 1153–1171
Citations Over TimeTop 10% of 2009 papers
Mark J. Mulvihill, Andrew Cooke, Maryland Rosenfeld-Franklin, Elizabeth Buck, K.W. Foreman, Darla Landfair, Matthew O’Connor, Caroline Pirritt, Yingchaun Sun, Yan Yao, Lee D. Arnold, Neil W. Gibson, Qunsheng Ji
Abstract
OSI-906 is a novel, potent, selective and orally bioavailable dual IGF-1R/IR kinase inhibitor with favorable preclinical drug-like properties, which has demonstrated in vivo efficacy in tumor models and is currently in clinical testing.
Related Papers
- → A comparison of in vivo and in vitro methods for determining availability of iron from meals(1981)109 cited
- → Studies on pharmacokinetics of sulfonated aluminum phthalocyanine in a transplantable mouse tumor by in vivo fluorescence(1993)8 cited
- → In vivo analysis of skin microcirculation in rats and mice(2008)2 cited
- → In Vivo Electroporation: A Convenient Method for Gene Transfer to Testicular Cells in Mice(1996)17 cited
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)